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Introduction
Dental infections assume a mixed form involving both
anaerobes and aerobes. Anaerobes are often isolated from
cases with dental infections, at the ratio of about 2:1. If
Streptococcus intermedius and S. constellatus, which are
Streptococcus species found in the oral cavity, are clas-
siﬁed as anaerobes, slightly more than 80% of all dental
infections involve anaerobes. Among anaerobes, the per-
centage of b-lactamase-producing bacteria of Prevotella
species has been rising, and the activities of cephems and
penicillins (which are often used to control dental and
oral infections) against the pathogens of these infections
have been decreasing. In dental infection cases, inﬂam-
mation is often conﬁned to the alveolus. If appropriate
surgical manipulations (such as incision and drainage) and
antibacterial chemotherapy are applied, dental infections
often subside within several days. However, depending on
host factors and delayed initiation of therapy, dental
infections can follow a severe course, occasionally lead-
ing to quite serious infections such as phlegmon and
necrotizing fasciitis. As inﬂammation persists and
becomes more severe, the frequency of anaerobe isolation
becomes higher.
Morbid conditions of dental infections
Inﬂammation often spreads to other areas from sites of
dental caries, periodontitis and pericoronitis. Dental
infections can be divided into four groups in Japan (Groups
1 through 4).
Group 1: Periodontitis
Periodontitis is subdivided into apical periodontitis (arising
from the infected tooth pulp) and marginal periodontitis
(arising from periodontitis alveolar pyorrhea).
Group 2: Pericoronitis
The term pericoronitis refers mainly to infections of
wisdom teeth caused primarily by wisdom tooth impac-
tions. This condition involves formation of a pocket
around the crown of a wisdom tooth and presents ery-
thema, swelling and pus of the gingival tissue around the
crown. Closed abscesses can also form, but this rarely
happens.
Group 3: Jaw inﬂammation
Jaw inﬂammation is an outcome of the spread of peri-
odontitis (Group 1) or pericoronitis (Group 2). Inﬂamma-
tion within the jawbone leads to perforation of the cortical
bone and spreads along the periosteum. Subperiosteal
abscess formation is common.
Group 4: Phlegmon around the jawbone
This category of infection is an outcome of the spread of
Group 2 or 3 dental infection. Infection within the jawbone
spreads to the sublingual spaces and then to the sub-
mandibular and submental spaces.
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Dental infection pathogens
As shown in Table 1, dental infections are frequently
attributable to Streptococcus species (Streptococcus ang-
inosus group: S. constellatus, S. intermedius, S. angino-
sus), Peptostreptococcus, Parvimonas, Peptoniphilus and
Prevotella. The frequency of isolation (number of iso-
lated strains/number of samples tested) is high for
Streptococcus species (86%), anaerobic gram-positive
cocci (Peptostreptococcus sp., Micromonas spp., Pep-
toniphilus spp.; 77%) and Prevotella spp. (ca. 66%),
indicating that these bacteria are major dental infection
pathogens. Porphyromonas spp., Fusobacterium spp.,
Eubacterium spp. and so on are also isolated from dental
infection cases.
Susceptibilities of anaerobes (major dental infection
pathogens) to drugs
Resistance to b-lactam drugs is seen with Streptococcus
species. The MIC of cefaclor against Streptococcus species
is high (MIC90: 100 lg/mL). The MIC90 of cephems after
cefaclor ranges from 0.78 to 3.13 lg/mL. The MIC90 of
ampicillin (ABPC) is about 1.56 lg/mL. The resistance of
other S. anginosus group (isolated most frequently from
dental infection cases) bacteria is not strong, with the
MIC90 against this group remaining at about 0.20 lg/mL.
No tendency for drug resistance is seen in anaerobic
gram-positive cocci such as Peptostreptococcus sp.
Prevotella spp. has a high b-lactamase positive rate
(over 40%) [1] (Table 2).
b-Lactam drugs
Drugs with high activities against Streptococcus species
and anaerobes found in the oral cavity are optimal for
treating dental infections. Although the MIC of cephems
and penicillins against Prevotella species (often isolated
from dental infection cases) has been rising, it is not
unreasonable to select cephems or penicillins as ﬁrst-line
drugs for the treatment of mild to moderate dental infec-
tions indicated for oral antibacterial agent therapy. Ade-
quate efﬁcacy can be expected if treatment with these drugs
is combined, whenever possible, with local manipulations
aimed at reducing the density of pathogenic bacteria at the
focus of infection (e.g., root canal opening, decompression
of closed abscess, and incision to eliminate pus) [2].
Selection of drugs for treating mild to moderate dental
infections indicated for oral antibacterial agent therapy
If active stage inﬂammation does not respond to penicillins
or cephems, it is advisable to select FRPM (450 mg/day) in
view of the presence of b-lactamase-producing bacteria.
Table 1 Bacteria isolated from 45 dental infection samples (closed abscess) and their frequencies of isolation (%)
Anaerobe No. of
strains
Frequency of
isolation (%)
Aerobe No. of
strains
Frequency
of isolation (%)
Peptostreptococcus species 35 77.8 Streptococcus species 39 86.7
P. anaerobius 6 13.3 S. constellatus 16 35.6
Peptostreptococcus 3 6.7 S. mitis 13 28.9
Parvimonas micra 23 51.1 S. oralis 7 15.6
Peptoniphilus asaccharolyticus 3 6.7 S. anginosus 2 4.4
Prevotella 30 66.7 S. acidominimus 1 2.2
P. intermedia 17 37.8 G. haemolysans 4 8.9
Prevotella 5 11.1 G. morbillorum 3 6.7
P. melaninogenica 4 8.9 L. cremoris 1 2.2
P. oris 4 8.9 Coagulase-negative 2 4.4
Fusobacterium 11 24.4 Staphylococcus epidermidis 1 2.2
F. nucleatum 7 15.6 Neisseria species 3 6.7
F. necrophorum 2 4.4 H. Parahaemolyticus 1 2.2
F. varium 2 4.4 Aerobic gram-positive rods 1 2.2
Bacteroides 4 8.9
Porphyromonas gingivalis 6 13.3
Anaerobic gram-positive rods 8 17.8
Total number of anaerobes isolated: 94 strains Total number of aerobes isolated: 55 strains
Mean number of anaerobes isolated per case: 2.1 strains Mean number of aerobes isolated per case: 1.2 strains
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If remission stage inﬂammation does not respond to
penicillins or cephems, it is advisable to select azithro-
mycin (AZM) (500 mg/day), clarithromycin (CAM)
(400 mg/day), levoﬂoxacin (LVFX, 400 mg/day), tosu-
ﬂoxacin tosilate (TFLX) (600 mg/day), and so on, in view
of the presence of b-lactamase-producing bacteria and the
distribution of these drugs into the target tissue.
Mild to moderate jaw inﬂammation and phlegmon
around the jawbone
Jaw inﬂammation is an indication for oral antibacterial
drug therapy, if patients can open their mouths, do not
complain of intense swallowing pain and can ingest food
orally. In cases in which mouth-opening and swallowing
functions have been severely compromised, antibacterial
drug injection is necessary. For oral antibacterial drug
therapy, the regimen needs to be adjusted depending on the
severity of inﬂammation. For example, if penicillins are
administered orally, an increase in the dose level and/or the
frequency of dosing (to four times daily) is needed,
depending on severity (AMPC is administered at a daily
dose of 1000 or 1500 mg in 4 divided doses).
Severe jaw inﬂammation and phlegmon around
the jawbone (indications for antibacterial agent
injection)
With severe jaw inﬂammation or phlegmon presenting with
marked symptoms of acute inﬂammation, trismus (lock-
jaw) and dysphagia, hospitalization is desirable so that the
patients can receive adequate treatment. In cases with
severe phlegmon, it is essential to open the cavity. Needle
aspiration should be performed to collect samples and
perform incision and drainage. It is also necessary to pre-
pare smears for gram staining to predict the pathogens. In
cases in which drainage is possible, treatment starts with
ABPC. In cases in which drainage is not possible, peni-
cillins with a b-lactamase inhibitor are considered to be the
drugs of ﬁrst choice to have high antibacterial activities
(shown in Table 3), when the infections is severe, so that
adequate activity against b-lactamase-producing anaerobes
(e.g., Prevotella spp.) may be exerted. In practice,
however, penicillins with a b-lactamase inhibitor are not
Table 2 Susceptibility of Prevotella isolated from dental infection
cases (closed abscess) to each drug
Bacterium No. of
strains
Drug MIC range MIC50 MIC90
Prevotella 28 Meropenem B0.06 to 0.12 B0.06 B0.06
Imipenem B0.06 B0.06 B0.06
Cefepime B0.06 to[128 1 64
Cefditoren B0.06 to 16 0.5 8
SBT/CPZ B0.06 to 4 1 2
ABPC B0.06 to 128 B0.06 16
Azithromycin 0.25 to 64 0.5 8
Gatiﬂoxacin 0.12 to 2 0.5 0.5
Doxycycline B0.06 to 32 0.12 4
b-Lactamase positive rate: 12 (all positive on nitroceﬁn test and
acidometry)/28 strains (43%). MIC (lg/mL)
Table 3 b-Lactamase-producing bacteria and MIC of drugs containing a b-lactamase inhibitor
Bacterium No. b-Lactamase production MIC (lg/mL)
Nitroceﬁn Acidometry SBT/
ABPC
ABPC (Ratio) CVA-
AMPC
AMPC (Ratio) TAZ-
PIPC
PIPC (Ratio)
PCase CEPase
Prevotella intermedia Pre 1 + + + 2 32 (16) 0.5 32 (64) 1 32 (32)
Pre 2 + + + 1 32 (32) 0.5 32 (64) 1 32 (32)
Pre 4 + + + 2 64 (32) 0.5 32 (64) 2 64 (32)
Pre 6 + + + 2 32 (16) 0.5 32 (64) 1 64 (64)
Pre 7 + + + 0.5 2 (4) 0.12 8 (64) 1 16 (16)
Pre 8 + + + 0.5 2 (4) B0.06 4 (64) 1 16 (16)
Pre 9 + + + 1 8 (8) 0.5 32 (64) 1 32 (32)
Pre 15 + + + B0.06 0.5 (8) B0.06 2 (32) 0.5 2 (4)
P. melaninogenica Pre 18 + + + 0.5 1 (2) B0.06 2 (32) 1 8 (8)
Pre 19 + + + 4 64 (16) 1 128 (128) 2 128 (64)
P. oris Pre 22 + + + 2 128 (64) 2 128 (64) 2 128 (64)
P. buccae Pre 26 + + + 1 16 (16) 0.25 64 (256) 1 64 (64)
Modiﬁed from Ref. [3]
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covered by Japanese health insurance for dental infection
cases. Thus, carbapenems are often selected. In more
severe cases, CLDM needs to be used in combination with
these drugs, and carbapenems should be administered three
times daily because of their half-life.
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